Immunome holder plans $334K Rule 144 stock sale
Form 144 reports Jack P. Higgins’ planned Rule 144 sale of 13,200 Immunome common shares obtained via stock option exercise.
Rhea-AI Filing Summary
Immunome Inc. (IMNM) received a notice that Jack P. Higgins plans to sell up to 13,200 shares of common stock under Rule 144, with Fidelity Brokerage Services LLC acting as broker. The shares relate to a stock option exercise from September 10, 2025, paid in cash.
The filing lists Immunome common stock as quoted on NASDAQ and reports 113,577,629 shares of common stock outstanding, serving as the baseline for this planned sale.
Positive
- None.
Negative
- None.
Key Figures
Shares to be sold under Rule 144: 13,200 shares
Shares outstanding: 113,577,629 shares
Aggregate market value of securities to be sold: $334,224.00
+1 more
4 metrics
Shares to be sold under Rule 144
13,200 shares
Maximum Immunome common shares covered by Jack P. Higgins’ Form 144 notice
Shares outstanding
113,577,629 shares
Immunome common stock outstanding as referenced in the Form 144
Aggregate market value of securities to be sold
$334,224.00
Value associated with the 13,200 Immunome shares listed in the securities information section
Stock option exercise date
September 10, 2025
Date on which the 13,200 shares were acquired via stock option exercise for cash
Key Terms
Rule 144, stock option exercise, attorney-in-fact
3 terms
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
stock option exercise financial
"Common | 09/10/2025 | Stock Option Exercise | Issuer"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
attorney-in-fact regulatory
"as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jack P. Higgins"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Immunome Inc. (IMNM)'s latest Form 144 disclose?
It discloses that Jack P. Higgins plans to sell up to 13,200 shares of Immunome Inc. common stock under Rule 144, with Fidelity Brokerage Services LLC as broker. The shares are tied to a stock option exercise completed on September 10, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.